Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Sep;58(9):2202-2207.
doi: 10.1111/trf.14652. Epub 2018 May 6.

Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively

Markus Eickmann  1 , Ute Gravemann  2 , Wiebke Handke  2 , Frank Tolksdorf  3 , Stefan Reichenberg  3 , Thomas H Müller  2 , Axel Seltsam  2
Affiliations
Comparative Study

Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively

Markus Eickmann et al. Transfusion. 2018 Sep.

Abstract

Background: Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have been identified as potential threats to blood safety. This study investigated the efficacy of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate EBOV and MERS-CoV in platelet concentrates (PCs) and plasma, respectively.

Study design and methods: PCs and plasma were spiked with high titers of cell culture-derived EBOV and MERS-CoV, treated with various light doses of ultraviolet C (UVC; THERAFLEX UV-Platelets) or methylene blue (MB) plus visible light (MB/light; THERAFLEX MB-Plasma), and assessed for residual viral infectivity.

Results: UVC reduced EBOV (≥4.5 log) and MERS-CoV (≥3.7 log) infectivity in PCs to the limit of detection, and MB/light decreased EBOV (≥4.6 log) and MERS-CoV (≥3.3 log) titers in plasma to nondetectable levels.

Conclusions: Both THERAFLEX UV-Platelets (UVC) and THERAFLEX MB-Plasma (MB/light) effectively reduce EBOV and MERS-CoV infectivity in platelets and plasma, respectively.

PubMed Disclaimer

Conflict of interest statement

FT and SR are employees of Macopharma, the manufacturer and distributor of the THERAFLEX technologies for PI. UG, WH, THM, and AS received project grants from the “Forschungsgemeinschaft der DRK‐Blutspendedienste e.V.” and from Macopharma for the development of the UVC‐based PI technology for platelets. The other authors have disclosed no conflicts of interest.

References

    1. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49 Suppl 2:1S‐29S. - PubMed
    1. Stramer SL. Current perspectives in transfusion‐transmitted infectious diseases: emerging and re‐emerging infections. ISBT Sci Ser 2014;9:30‐6. - PMC - PubMed
    1. Rabaan AA. Middle East respiratory syndrome coronavirus: five years later. Exp Rev Resp Med 2017;11:901‐12. - PubMed
    1. Rha B, Rudd J, Feikin D, et al. Update on the epidemiology of Middle East respiratory syndrome coronavirus (MERS‐CoV) infection, and guidance for the public, clinicians, and public health authorities—January 2015. MMWR Morb Mortal Wkly Rep 2015;64:61‐2. - PMC - PubMed
    1. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967‐76. - PubMed

Publication types

MeSH terms